Allison, Honjo Win Nobel Prize for Research on Immune Checkpoints
Immunotherapy pioneers James P. Allison, PhD, and Tasuku Honjo, MD, PhD, have won the 2018 Nobel Prize in Physiology or Medicine for their research that eventually led to the use of immune checkpoint inhibitors to treat cancer.
James Allison, PhD
Immunotherapy pioneers James P. Allison, PhD, and Tasuku Honjo, MD, PhD, have won the 2018 Nobel Prize in Physiology or Medicine for their research that eventually led to the use of immune checkpoint inhibitors to treat cancer. The Nobel Assembly at Karolinska Institutet announced the award in a statement Monday.
“Cancer kills millions of people every year and is one of humanity’s greatest health challenges,” the committee said. “By stimulating the inherent ability of our immune system to attack tumor cells, this year’s Nobel Laureates have established an entirely new principle for cancer therapy.”
Allison, chair of Immunology and executive director of the Immunotherapy Platform at The University of Texas MD Anderson Cancer Center, is best known for his work in T-cell response mechanisms and his discovery that blocking the signaling of the immune checkpoint protein CTLA-4 improved antitumor immune responses. His research led to the development of ipilimumab (Yervoy), the first FDA-approved immune checkpoint inhibitor. The agency approved ipilimumab the treatment of advanced melanoma in 2011.
Honjo, a professor in the Department of Immunology and Genomic Medicine at Japan’s Kyoto University Graduate School of Medicine, discovered PD-1 on the surface of immune cells in 1992 and later demonstrated that the protein inhibited immune response. His research eventually led to the development of pembrolizumab (Keytruda) and nivolumab (Opdivo), both of which were approved for the treatment of advanced melanoma in 2014.
Tasuku Honjo, MD, PhD
Clinical trials have shown that PD-1 blockade has resulted in positive outcomes for patients with lung cancer, renal cancer, and lymphoma.
Allison said in a press conference that he first learned the Nobel Committee’s decision from a phone call from his son at 5:30 a.m. He was still in shock hours later.
“It still hasn’t completely dawned on me,” he said. “As a basic scientist, to have my work impact people is one of the best things I can think about. It’s every scientist’s dream to do fundamental work that’s important, but then to have it translate into helping people is all that much better. Then to have that work recognized by the Nobel Committee is going to bring attention to the issues, the importance of basic science, and that there is hope for cancer patients.”
In 2015, Allison won the Lasker-DeBakey Clinical Medical Research Award honoring investigators whose contributions have improved clinical treatment. That same year, he won ASCO’s Science of Oncology Award and the Pezcoller Foundation—AACR International Award for Cancer Research. He was also recognized as a 2014 Giants of Cancer Care® in Scientific Advances. Honjo and Allison were joint recipients of the first Tang Prize for Biopharmaceutical Science in 2014.
Honjo won the Smalley Award from the Society for Immunotherapy of Cancer in 2015 and the Keio Medical Science Prize in 2016. That award from Keio University recognizes researchers who have made an outstanding contribution to medicine or the life sciences. Honjo is the eighth Keio Prize winner to later become a Nobel Laureate.
Final results from the phase III KEYNOTE-006 trial of patients with unresectable stage III/IV advanced melanoma showed that frontline pembrolizumab continues to demonstrate long-term efficacy. At 2 years, patients assigned to pembrolizumab had an overall survival (OS) of 55% versus 43% for those assigned to ipilimumab.1
The FDA approved pembrolizumab in this setting in 2015 based on results from this trial.
In the study that led to the approval of ipilimumab for patients with unresectable or metastatic melanoma following at least 1 prior systemic treatment, OS was longer with ipilimumab alone compared with the experimental tumor vaccine gp100 (HR, 0.66; P = .0026).2 Patients treated with ipilimumab alone had a median OS of 10 months compared with 6 months for those treated with gp100.
Follow-up studies have since shown that 20% of patients survive at least 3 years posttreatment, with many living for 10 years and beyond. Subsequent research has led to agents targeting additional immune checkpoints, often PD-1 and PD-L1, to treat a range of cancers including head and neck, gastric kidney, bladder, gastric, liver, colorectal, and cervical cancers, and Hodgkin lymphoma.
Allison said that 1 patient with metastatic melanoma from the phase I trial is still alive almost 19 years later following a single dose of ipilimumab. He said that clinicians and investigators have come to accept immunotherapy as the fourth pillar of cancer care along with radiation, surgery, and chemotherapy.
“What we’re looking forward to is combinations, not just of multiple checkpoints but of checkpoints with radiation, checkpoints with chemotherapy, [and] checkpoints with genetically targeted small molecule drugs,” he said. “Immunotherapy is going to be part, it’s not going to replace the others, but it’s going to be part of the therapy that essentially all cancer patients are going to be receiving in 5 years.”
References
- Schachter J, Ribas A, Long GV, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet Oncol. 2017;390(10105):1853-1862. doi: 10.1016/S0140-6736(17)31601-X.
- McDermott D, Haanen J, Chen TT, et al. Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). Ann Oncol. 2013;24(10):2694-2698.
